Moderna presents personalized mRNA cancer vaccine results at ESMO
What happened
Clinical trial results showed that a personalized mRNA cancer vaccine, intismeran autogene, combined with Keytruda, reduced the risk of melanoma recurrence or death by 42% compared to Keytruda alone. The vaccine is custom-built for each patient based on tumor genetic markers. Moderna and Merck are currently engaging with regulatory authorities following these results.
From bdnews24.com
Why it matters
The positive clinical data strengthens the regulatory approval pathway for the therapy. Analysts at RBC Capital Markets anticipate the US Food and Drug Administration may approve the treatment next year. Moderna and Merck are collaborating on the joint development and testing of these personalized mRNA cancer vaccines.
From bdnews24.com
Who's involved
- ModernaDeveloped the personalized mRNA cancer vaccine.
- Memorial Sloan Kettering Cancer CenterPartnered with Moderna on personalized cancer vaccine trials.
- RBC Capital MarketsProvided analyst coverage and expectations for the company.
- MerckPartnered with Moderna to jointly develop the vaccine.
- FDARegulatory authority expected to review the therapy.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- ModernaSpeculative
Shares might experience price changes following the clinical trial results.
- RBC Capital MarketsSpeculative
The stock drop might necessitate target revisions by the investment bank.
Keep exploring
The entities involved
-
Moderna
American biotechnology company
-
Memorial Sloan Kettering Cancer Center
cancer treatment and research institution in New York City, United States
Nothing else this week.
Related events
- Moderna and Merck announced a partnership on their mRNA cancer vaccine trial, leading to analyst rating hikes.
- Moderna announced a collaboration with Merck KGaA regarding a personalized cancer vaccine platform.
- Moderna and BioNTech are recognized as leaders in the personalized cancer vaccine space.
- Moderna and Merck are developing cancer vaccines in partnership, while Moderna is also seeking approval for its seasonal influenza vaccine.
- The European Medicines Agency is reviewing mRNA vaccine trials reported by Moderna and MSD.